决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases.
嵌合抗原受体(CAR)T细胞疗法在治疗多种血液系统恶性肿瘤方面取得的成功,在实体瘤中一直难以复制,部分原因是T细胞耗竭并最终导致功能障碍。
嵌合抗原受体(CAR)T细胞疗法在治疗多种血液系统恶性肿瘤方面取得的成功,在实体瘤中一直难以复制,部分原因是T细胞耗竭并最终导致功能障碍。为了对抗肿瘤微环境中的T细胞功能障碍,我们通过工程化改造使CAR T细胞分泌白细胞介素-10(IL-10),从而对其进行代谢装甲。我们发现,IL-10 CAR T细胞能够在肿瘤微环境中维持完整的线粒体结构和功能,并以线粒体丙酮酸载体依赖的方式增加氧化磷酸化。IL-10的分泌促进了CAR T细胞的增殖和效应功能,在多种癌症类型的同基因和异种移植小鼠模型中,包括结肠癌、乳腺癌、黑色素瘤和胰腺癌,导致已建立的实体瘤和转移性癌症完全消退。IL-10 CAR T细胞还在淋巴器官中诱导了干细胞样记忆反应,赋予了对肿瘤再攻击的持久保护。我们的结果建立了一种通过代谢装甲来对抗CAR T细胞功能障碍的通用方法,从而实现实体瘤的根除和持久的免疫保护。
The success of chimeric antigen receptor (CAR) T cell therapy in treating several hematopoietic malignancies has been difficult to replicate in solid tumors, in part because of T cell exhaustion and eventually dysfunction. To counter T cell dysfunction in the tumor microenvironment, we metabolically armored CAR T cells by engineering them to secrete interleukin-10 (IL-10). We show that IL-10 CAR T cells preserve intact mitochondrial structure and function in the tumor microenvironment and increase oxidative phosphorylation in a mitochondrial pyruvate carrier-dependent manner. IL-10 secretion promoted proliferation and effector function of CAR T cells, leading to complete regression of established solid tumors and metastatic cancers across several cancer types in syngeneic and xenograft mouse models, including colon cancer, breast cancer, melanoma and pancreatic cancer. IL-10 CAR T cells also induced stem cell-like memory responses in lymphoid organs that imparted durable protection against tumor rechallenge. Our results establish a generalizable approach to counter CAR T cell dysfunction through metabolic armoring, leading to solid tumor eradication and long-lasting immune protection.
MEMBER ACCOUNT
登录成功会直接打开下一页。